---
title: "Minerva Surgical, Inc. (UTRS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/UTRS.US.md"
symbol: "UTRS.US"
name: "Minerva Surgical, Inc."
industry: "Health Care Equipment"
datetime: "2026-05-20T11:26:55.098Z"
locales:
  - [en](https://longbridge.com/en/quote/UTRS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/UTRS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/UTRS.US.md)
---

# Minerva Surgical, Inc. (UTRS.US)

## Company Overview

Minerva Surgical, Inc. provides a suite of devices to treat the root causes of abnormal uterine bleeding in the United States. The company provides Minerva Endometrial Ablation System, a technology that uses three methods of tissue ablation; Symphion System that is designed for fluid management, direct intrauterine pressure monitoring, and bladeless resection work; and Genesys HTA, an endometrial ablation device for the treatment of a wider range of uterine cavities. It also offers Resectr, a tissue resection device to diagnose and treat polyps; and HERizon electronic disposable hysteroscope, image processor, Hysto-Kit, and endoscopic accessories that helps gynecologists to evaluate abnormal uterine bleeding and provide care.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [minervasurgical.com](https://minervasurgical.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: D (0.60)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 163 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.11% |  |
| Net Profit YoY | -96.08% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8.88 |  |
| Revenue | 51693000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -160.07% | E |
| Profit Margin | -64.71% | E |
| Gross Margin | 51.97% | B |
| Revenue YoY | 3.11% | C |
| Net Profit YoY | -96.08% | E |
| Total Assets YoY | -13.15% | E |
| Net Assets YoY | -5.96% | D |
| Cash Flow Margin | 115.79% | C |
| OCF YoY | 3.11% | C |
| Turnover | 0.66 | B |
| Gearing Ratio | 72.17% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Minerva Surgical, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.11%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-96.08%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8.88",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "51693000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-160.07%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-64.71%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "51.97%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "3.11%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-96.08%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-13.15%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.96%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "115.79%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "3.11%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.66",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "72.17%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/UTRS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/UTRS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/UTRS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/UTRS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**